Back to Search Start Over

Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.

Authors :
Rhee, Hyungjin
Cho, Eun-Suk
Nahm, Ji Hae
Jang, Mi
Chung, Yong Eun
Baek, Song-Ee
Lee, Sunyoung
Kim, Myeong-Jin
Park, Mi-Suk
Han, Dai Hoon
Choi, Jin-Young
Park, Young Nyun
Source :
Journal of Hepatology. Jan2021, Vol. 74 Issue 1, p109-121. 13p.
Publication Year :
2021

Abstract

Despite the clinical and genetic significance of macrotrabecular-massive hepatocellular carcinoma (MTM-HCC), its characteristics on imaging have not been described. This study aimed to characterise MTM-HCC on gadoxetic acid-enhanced MRI and to evaluate the diagnostic accuracy and prognostic value of these imaging characteristics. We enrolled 3 independent cohorts from 2 tertiary care centres. The 3 cohorts consisted of a total of 476 patients who underwent gadoxetic acid-enhanced MRI and surgical resection for treatment-naïve single HCCs. Independent review of histopathology and MRI by 2 reviewers was performed for each cohort, and inter-reader agreement was evaluated. Based on the result of MRI review in the training cohort (cohort 1), we developed 2 diagnostic criteria for MTM-HCC and evaluated their prognostic significance. The diagnostic performance and prognostic significance were validated in 2 validation cohorts (cohorts 2 and 3). We developed 2 diagnostic MRI criteria (MRIC) for MTM-HCC: MRIC-1, ≥20% arterial phase hypovascular component; MRIC-2, ≥50% hypovascular component and 2 or more ancillary findings (intratumoural artery, arterial phase peritumoural enhancement, and non-smooth tumour margin). MRIC-1 showed high sensitivity and negative predictive value (88% and 95% in the training cohort, and 88% and 97% in the pooled validation cohorts, respectively), whereas MRIC-2 demonstrated moderate sensitivity and high specificity (47% and 94% in the training cohort, and 46% and 96% in the pooled validation cohorts, respectively). MRIC-2 was an independent poor prognostic factor for overall survival in both training and pooled validation cohorts. Using gadoxetic acid-enhanced MRI findings, including an arterial phase hypovascular component, we could stratify the probability of MTM-HCC and non-invasively obtain prognostic information. Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a histopathologic subtype of HCC characterised by aggressive biological behaviour and poor prognosis. We developed imaging criteria based on liver MRI that could be used for the non-invasive diagnosis of MTM-HCC. HCCs showing imaging findings of MTM-HCC were associated with poor outcomes after hepatic resection. • Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is an aggressive subtype of HCC. • We revealed gadoxetic acid-enhanced MRI findings related to MTM-HCC. • Using MRI findings, we could non-invasively stratify the probability of MTM-HCC. • HCC without an arterial phase hypovascular component is highly unlikely to be MTM-HCC. • MRI findings of MTM-HCC could be a useful prognostic factor after surgical resection. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01688278
Volume :
74
Issue :
1
Database :
Academic Search Index
Journal :
Journal of Hepatology
Publication Type :
Academic Journal
Accession number :
147182877
Full Text :
https://doi.org/10.1016/j.jhep.2020.08.013